samedan logo

home > news > detailed info

Oncology: Tollys earns ‘Best-in-class therapeutic innovation’ award from MATWIN for its drug candidate TL-532


Confirmation by MATWIN’s panel of scientific and industry experts of therapeutic potential of TL-532 major boost for Tollys, supports moving flagship product towards clinical phase

Lyon, France, May 18, 2021 – Tollys, a biopharmaceutical company responsible for developing TL-532, the first anti-cancer immunotherapy based on a synthetic toll-like receptor 3 (TLR3) specific agonist, today announces that it has been awarded the ‘Best-in-Class Therapeutic Innovation’ prize by the MATWIN international board.

This prize recognizes the medical importance and industrial development potential of Tollys’ TLR3 specific agonist, TL-532. The MATWIN program - which is supported by an historic partnership with 13 international laboratories including: Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Exact Sciences, Gilead, GSK, Nanostring Technologies, Novartis, Pierre Fabre, Pfizer, Roche and Sanofi, has given Tollys the opportunity for direct contact with the world’s leading experts in cancer treatment.

“We feel very honored to have been awarded this prize. We would like to thank MATWIN and the members of its international board for recognizing us in this way. The MATWIN program has provided us with the chance to discuss and confirm our scientific decisions and development plans with leading experts in the field, and enabled us to expand our network of potential partners,” explains Tollys CEO Vincent Charlon.

This positive evaluation from the MATWIN international board has given backing to some key parts of Tollys’ strategy. It is yet another step completed prior to the clinical trial, alongside recent recruitments in key positions, the establishment of a scientific advisory board and the approval of the preclinical program - via the European Medicine Agency’s Scientific Advice scheme.
  • TLR3 is one of the preferred therapeutic targets in immuno-oncology. It has been clinically validated and can trigger the release of antigens in tumor cells, causing an immune response against the tumor. This separates TLR3 from other TLRs and PRRs (Pattern Recognition Receptors, such as RIG-I and Sting), which mostly act as adjuvants without a preferential apoptotic action on cancer cells
  • TL-532 is the only synthetic specific TLR3 agonist. This sets it apart from other TLR3 agonists tested to date
  • TL-532 has significant potential. TL-532’s capacity to trigger an immune response against the patient’s specific tumor antigens could create an immune response in patients without pre-existing anti-tumor immunity; significantly increasing the percentage of patients who might benefit from checkpoint inhibitors (PD1 and PDL1 inhibitors)
  • A two-stage development strategy has been put in place. TL-532 will initially undergo clinical testing with intratumoral delivery. Tollys has already completed major validation steps and will continue its studies into possible systemic delivery methods for TL-532. These will be clinically tested during a second stage
email 41 quai Fulchiron, 69005, Lyon
Print this page
Send to a friend
News and Press Releases

More than 10% of goods mislabelled every year, say 76% of manufacturers

London, UK, 7th June 2021 – More than three-quarters (76%) of IT directors in manufacturing across UK, US, Germany, and France admit that more than 10% of their organisation’s goods are labelled incorrectly every year. This rises to more than 25% of goods for a quarter (26%) of organisations, according to new research from NiceLabel, which polled 300 IT directors working for manufacturers across a range of sectors, including retail, pharmaceutical, food and beverage, automotive, medical device and chemicals.
More info >>

White Papers

Clinical Trial Disclosure Management: Build vs. Buy


Because software development is our core competency, TrialScope continues to make a significant investment in our technology. We employ agile methodologies to ensure that we can maintain a continuing level of responsiveness as disclosure requirements evolve across registries and regions.
More info >>

Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement